July 9 (Reuters) - Moderna said on Thursday it has secured a European Commission contract to supply its respiratory syncytial ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) jumped 2.6% in the afternoon session after the European ...

Moderna gains fresh market attention after a unanimous flu vaccine panel vote strengthens confidence in its mRNA vaccine ...

All nine members of the committee unanimously voted to recommend Moderna's new mRNA influenza vaccine for adults 50 and over.

When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.

By Christy Santhosh and Mariam Sunny June 18 (Reuters) - Advisers to the U.S. Food and Drug Administration on Thursday backed approval of Moderna's flu vaccine for adults aged 50 and older, saying its ...

Moderna's flu vaccine may not fuel a further recovery for the hard-hit COVID-19-affected stock.

Find the latest covid vaccine news from Fast company. See related business and technology articles, photos, slideshows and ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. BOSTON — Over the last year, venture ...

Moderna surged as investors turned eyed potential demand for a vaccine to protect against bird flu after the US reported its ...

Moderna (NASDAQ:MRNA) stock is jumping again. Shares are up 9% today, trading near $57 in the Tuesday afternoon session. That extends a remarkable 2026 run for the mRNA pioneer. The move pushes ...

Moderna has delivered a sharp 148.1% gain year to date, yet its low value score and rich market multiples suggest the stock ...